Equities

Inotiv Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Inotiv Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.306
  • Today's Change0.035 / 13.04%
  • Shares traded3.87k
  • 1 Year change-90.06%
  • Beta4.2326
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

  • Revenue in USD (TTM)514.03m
  • Net income in USD-69.37m
  • Incorporated1975
  • Employees1.95k
  • Location
    Inotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
  • Phone+1 (317) 463-4527
  • Fax+1 (765) 497-1102
  • Websitehttps://www.inotiv.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
StimCell Enegetics Inc0.00-935.22k8.98m0.00---------0.0461-0.04610.00-0.07380.00-------2,062.23-844.03-----------18,037.46---17.22---------297.42------
Transcode Therapeutics Inc0.00-27.16m9.05m7.00--5.77-----354.09-354.090.001.710.00----0.00-592.26-153.21-1,387.56-219.22------------0.00------9.49------
Lunai Bioworks Inc0.00-125.52m9.24m29.00---------7.14-7.140.00-0.56020.00----0.00-212.74-75.79-361.75-85.18-----------23.72---------101.31------
Cardio Diagnostics Holdings Inc15.79k-6.55m9.50m13.00--1.13--601.36-4.07-4.070.00974.610.0024--1.251,214.62-98.75---104.31-------41,495.31-----440.220.00--104.39---0.079------
Liminatus Pharma Inc0.00-2.27m9.54m-----------0.0872-0.08720.00-0.06080.00-------77.46-----------------12.30--------28.85------
LianBio - ADR0.00-87.98m9.83m163.00--0.0482-----0.8195-0.81950.001.890.00----0.00-28.62---35.22--------------0.00------43.82------
Imunon Inc0.00-14.33m10.10m25.00--2.68-----10.20-10.200.001.230.00----0.00-122.58-57.72-208.59-70.83-------7,752.42----0.00------4.58---38.98--
BioVie Inc0.00-17.48m10.11m13.00--0.5245-----5.13-5.130.002.550.00----0.00-72.35-260.69-79.73-454.45------------0.00------45.73------
Inotiv Inc514.03m-69.37m10.52m1.95k--0.0965--0.0205-2.02-2.0215.003.170.682110.377.71264,281.20-9.21-18.23-16.14-23.6423.4926.43-13.50-27.500.2218-0.62980.7918--4.5453.3636.72--21.79--
OSR Holdings Inc2.52m-15.21m10.56m----0.1184--4.18-1.73-1.730.19393.460.0255-------22.03---34.38--18.35---864.91--0.2009--0.0313-------697.08------
Phio Pharmaceuticals Corp0.00-7.95m10.98m5.00--0.5997-----2.73-2.730.001.700.00----0.00-91.57-73.65-107.58-86.34------------0.00------33.96---57.49--
Ainos Inc113.04k-14.96m11.03m44.00--0.754--97.60-4.29-4.290.03072.100.00420.123,768.002,569.09-55.34-38.46-60.63-55.2282.6235.93-13,231.35-1,122.702.67-19.920.5227---83.0212.06-7.93--10.22--
Longeveron Inc1.44m-21.34m11.63m25.00--1.15--8.09-1.34-1.340.09090.47320.0632--6.6557,480.00-93.88-70.26-114.04-83.9274.8844.57-1,485.11-683.81----0.00--237.38-15.76-10.86--51.32--
Soligenix Inc0.00-11.46m11.80m14.00--1.52-----3.66-3.660.000.77050.00----0.00-105.25-73.79-165.82-151.46--22.19---1,147.93----0.00---85.78-51.89-34.62------
Chemomab Therapeutics Ltd - ADR0.00-10.09m12.06m16.00--1.07-----5.87-5.870.001.820.00----0.00-60.63---72.61--------------0.00------42.43------
Data as of Mar 02 2026. Currency figures normalised to Inotiv Inc's reporting currency: US Dollar USD

Institutional shareholders

16.00%Per cent of shares held by top holders
HolderShares% Held
Balyasny Asset Management LPas of 31 Dec 20251.47m4.28%
The Vanguard Group, Inc.as of 31 Dec 20251.22m3.56%
GSA Capital Partners LLPas of 31 Dec 2025509.89k1.48%
UBS Securities LLCas of 31 Dec 2025429.93k1.25%
Massar Capital Management LPas of 31 Dec 2025342.70k1.00%
Renaissance Technologies LLCas of 31 Dec 2025338.80k0.99%
Vantage Point Financial LLCas of 31 Dec 2025336.55k0.98%
Geode Capital Management LLCas of 31 Dec 2025328.77k0.96%
BlackRock Fund Advisorsas of 31 Dec 2025265.08k0.77%
Ennismore Fund Management Ltd.as of 31 Dec 2024257.00k0.75%
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.